# | Title | Journal | Year | Citations |
---|
1 | Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 | Annals of Oncology | 2013 | 2,805 |
2 | ESMO consensus guidelines for the management of patients with metastatic colorectal cancer | Annals of Oncology | 2016 | 2,545 |
3 | Estimates of the cancer incidence and mortality in Europe in 2006 | Annals of Oncology | 2007 | 2,332 |
4 | The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014 | Annals of Oncology | 2015 | 2,122 |
5 | Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2017 | 1,744 |
6 | Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic | Annals of Oncology | 2019 | 1,742 |
7 | Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2018 | 1,571 |
8 | Prevalence of pain in patients with cancer: a systematic review of the past 40 years | Annals of Oncology | 2007 | 1,506 |
9 | Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2017 | 1,456 |
10 | Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 | Annals of Oncology | 2015 | 1,449 |
11 | Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer | Annals of Oncology | 2004 | 1,407 |
12 | Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2016 | 1,351 |
13 | Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2019 | 1,241 |
14 | ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making | Annals of Oncology | 2012 | 1,233 |
15 | Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2010 | 1,220 |
16 | Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2016 | 1,212 |
17 | Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China | Annals of Oncology | 2020 | 1,188 |
18 | Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 | Annals of Oncology | 2009 | 1,184 |
19 | Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2015 | 1,168 |
20 | Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies | Annals of Oncology | 2015 | 1,136 |
21 | Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2017 | 1,126 |
22 | Cancer incidence and mortality in Europe, 2004 | Annals of Oncology | 2005 | 1,046 |
23 | Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2014 | 1,039 |
24 | Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial | Annals of Oncology | 2014 | 1,022 |
25 | Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2015 | 1,015 |
26 | Non-Invasive Analysis of Acquired Resistance to Cancer Therapy By Sequencing of Plasma Dna | Annals of Oncology | 2014 | 987 |
27 | Heating the patient: a promising approach? | Annals of Oncology | 2002 | 983 |
28 | HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target | Annals of Oncology | 2008 | 931 |
29 | Man against machine: diagnostic performance of a deep learning convolutional neural network for dermoscopic melanoma recognition in comparison to 58 dermatologists | Annals of Oncology | 2018 | 915 |
30 | Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2014 | 910 |
31 | Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005 | Annals of Oncology | 2005 | 909 |
32 | Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab | Annals of Oncology | 2017 | 908 |
33 | Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer | Annals of Oncology | 2004 | 900 |
34 | Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA) | Annals of Oncology | 2013 | 895 |
35 | 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) | Annals of Oncology | 2018 | 891 |
36 | Use of complementary and alternative medicine in cancer patients: a European survey | Annals of Oncology | 2005 | 875 |
37 | Worldwide burden of cervical cancer in 2008 | Annals of Oncology | 2011 | 875 |
38 | Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2013 | 874 |
39 | 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) | Annals of Oncology | 2017 | 865 |
40 | ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up | Annals of Oncology | 2016 | 862 |
41 | Body mass index and survival in women with breast cancer—systematic literature review and meta-analysis of 82 follow-up studies | Annals of Oncology | 2014 | 857 |
42 | De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 | Annals of Oncology | 2017 | 844 |
43 | Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry | Annals of Oncology | 2019 | 842 |
44 | Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2016 | 834 |
45 | Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2013 | 833 |
46 | Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007 | Annals of Oncology | 2007 | 825 |
47 | Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study | Annals of Oncology | 2013 | 792 |
48 | Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA | Annals of Oncology | 2020 | 770 |
49 | Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy | Annals of Oncology | 2016 | 765 |
50 | 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) | Annals of Oncology | 2020 | 761 |